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Polypharmacy and inappropriate medication use in patients with dementia: an underresearched 
problem 
 
Abstract 
Multimorbidity and polypharmacy are increasingly prevalent across healthcare systems and settings 
as global demographic trends shift towards increased proportions of older people in populations. 
Numerous studies have demonstrated an association between polypharmacy and potentially 
inappropriate prescribing (PIP), and have reported high prevalence of PIP across settings of care in 
Europe and North America and, as a consequence, increased risk of adverse drug reactions, 
healthcare utilisation, morbidity and mortality. These studies have not focused specifically on people 
with dementia, despite the high risk of adverse drug reactions and PIP in this patient cohort. This 
narrative review considers the evidence currently available in the area, including studies examining 
prevalence of PIP in older people with dementia, how appropriateness of prescribing is assessed, the 
medications most commonly implicated, the clinical consequences, and research priorities to 
optimise prescribing for this vulnerable patient group. Although there has been considerable 
research effort to develop criteria to assess medication appropriateness in older people in recent 
years, the majority of tools do not focus on people with dementia. Of the limited number of tools 
available, most focus on the advanced stages of dementia in which life-expectancy is limited. The 
development of tools to assess medication appropriateness in people with mild-to-moderate 
dementia or across the full spectrum of disease severity represents an important gap in the research 
literature and is beginning to attract research interest, with recent studies considering the 
medication regimen as a whole, or misprescribing, overprescribing or underprescribing of certain 
medications/medication classes including anticholinergics, psychotropics, antibiotics and analgesics.  
Further work is required in development and validation of criteria to assess prescribing 
appropriateness in this vulnerable patient population, to determine prevalence of PIP in large 
cohorts of people with the full spectrum of dementia variants and severities and to examine the 
impact of PIP on health outcomes. 
Keywords 
Adverse drug reaction, comorbidity, dementia, inappropriate medication use, inappropriate 
prescribing, polypharmacy. 
Introduction 
The world’s population is ageing at an increasingly dramatic rate as fertility rates fall and people in 
high-, middle- and low-income countries are living longer [World Health Organization, 2015]. 
Multimorbidity, commonly defined as the presence of two or more chronic medical conditions 
[World Health Organization, 2015] and, as a consequence, polypharmacy (the prescribing of multiple 
medications) are increasingly prevalent across healthcare systems and settings in most developed 
countries [Cadogan et al.  2016] as demographic trends shift towards increased proportions of older 
persons in their populations.  Coupled with age-related changes in drug pharmacokinetics and 
pharmacodynamics, multimorbidity and polypharmacy are widely regarded as key predisposing 
factors for adverse drug reactions (ADRs) [Mangoni & Jackson, 2004; Viktil et al.  2007; Cherubini et 
al.  2011; Petrovic et al.  2012; Onder et al.  2013].  
It is widely recognised that there is no universally accepted definition of “polypharmacy” [Cadogan 
et al.  2016]; it has been defined as the prescribing of medications over a threshold number of four 
or five [Maher et al. 2014; Patterson et al. 2014], or may be considered conceptually to describe the 
prescribing of “many drugs” or “too many” drugs [Cadogan et al.  2016], introducing a dimension in 
which the appropriateness of the prescribing is taken into account [Aronson, 2004]. Irrespective of 
the lack of a universally recognised definition of the term, numerous studies have highlighted the 
association between polypharmacy and inappropriate medication use in older people [Cadogan et 
al.  2016; Bradley et al.  2012; Cahir et al.  2010]. Medicines are considered to be prescribed 
appropriately when they have a clear evidence-based indication, are cost-effective and well-
tolerated [O’Mahony & Gallagher, 2008]. Inappropriate medication use, inappropriate drug use 
(IDU), inappropriate prescribing (IP) and potentially inappropriate prescribing (PIP) are terms used to 
refer to suboptimal prescribing practices which include overprescribing, underprescribing and 
misprescribing of medications [Spinewine et al.  2007; Kaufmann et al.  2014].  The 
(in)appropriateness of prescribing for older people has received significant research attention in 
recent years, with numerous studies reporting high prevalence of PIP in acute and long-term care 
settings and in community-dwelling older people in Europe and North America and demonstrating 
its association with increased risk of ADRs, morbidity, mortality and healthcare utilisation [Fialova et 
al.  2005; Fu et al.  2007; Spinewine et al.  2007; Gallagher et al.  2008; Gallagher et al.  2011; 
Hamilton et al.  2011; García-Gollarte et al.  2012; Opondo et al.  2012; Hill-Taylor et al.  2013; 
Blanco-Reina et al.  2014; Galvin et al.  2014; Gosch et al.  2014; Kovačević et al.  2014; Shade et al.  
2014; Tommelein et al.  2015). However, few studies have focussed specifically on people with 
dementia [Montastruc et al.  2013].  
Dementia is an irreversible neurodegenerative disorder characterised by a cluster of signs and 
symptoms including difficulties in memory, disturbances in language, psychosocial and psychiatric 
changes, and impairments in activities of daily living [Burns & Iliffe,  2009; Wu et al.  2016]. It is 
commonly associated with other chronic medical conditions such as diabetes, chronic obstructive 
pulmonary disease, chronic cardiac failure, musculoskeletal disorders, and vascular disease [Bell et 
al. 2015; Doraiswamy et al. 2002; Schubert et al. 2006; Lee et al. 2009; Onder et al. 2012), and as a 
consequence, polypharmacy [Onder et al. 2013]. It has been reported that people with dementia 
take an average of 5-10 medications, of which 1-2 are prescribed for dementia and the remainder 
are indicated for the treatment of other comorbid medical conditions [Elmståhl et al. 1998; Lau et al. 
2010]. The use of multiple medications in this population raises a number of issues; memory loss, 
decline in intellectual function, and impaired judgement and language may cause difficulties in 
communicating symptoms or problems related to adverse effects of drugs [Ganjavi et al. 2007; 
Onder et al.  2011]. Furthermore, older people, and those with dementia in particular, are often 
excluded from clinical trials and guidelines, so the evidence base to guide prescribing for these 
patients is limited [Brauner et al.  2000; Marengoni & Onder, 2015]. Finally, people with dementia 
have a reduced life expectancy, which may impact on the risk-benefit profile of a medication; drugs 
for primary or secondary prevention may require years of treatment to demonstrate their benefit, 
and their use may be considered inappropriate if a patient is not expected to survive to realise this 
benefit [Currow & Abernethy, 2006; Fusco et al. 2009; Holmes, 2009; Onder et al. 2013].  
In this narrative review article we discuss the prevalence of PIP in older people with dementia, giving 
consideration to how appropriateness is assessed, the medications which are most commonly 
implicated in PIP, the clinical consequences of such prescribing, and research priorities to optimise 
prescribing for this vulnerable patient group. 
Search methodology 
A literature search was conducted using MEDLINE (1950–January 2016), EMBASE (1980– January 
2016), Web of Science (1981– January 2016), International Pharmaceutical Abstracts (1970– January 
2016) and the Cochrane Library of Systematic Reviews (1999–January 2016). The search terms used 
were “inappropriate”, “potentially inappropriate”, “dementia”, “Alzheimer”, “drugs”, “medicines”, 
“medications”, “prescribing”, “prescription”, “older”, “old”, “elderly”, “aged” and combinations 
thereof. Only articles in the English language were selected. No attempt was made to reject papers 
on the basis of methodology, e.g. not a randomized controlled trial, as some studies were 
descriptive in nature or were papers that were classified as commentaries.  
Medication appropriateness in people with dementia 
There has been considerable effort to develop criteria to classify the appropriateness of medication 
use in older people in recent years, resulting in the evolution and refinement of a number of tools. 
These utilise implicit (judgement-based) or explicit (criterion-based) measures of medication 
appropriateness, or a combination of both approaches [Kaufmann et al. 2014].  A recent systematic 
review found 46 available tools, each with limitations, strengths and weaknesses [Kaufmann et al. 
2014]. These tools varied in their target populations; while most named older people as target 
patients, just over 20% did not specify an age group. The majority (59%) did not specify healthcare 
setting, some focused on hospitalised patients, while others considered ambulatory care or long-
term care [Kaufman et al. 2014]. The Beers criteria [Beers et al. 1991; Beers, 1997; Fick et al. 2003; 
Campanelli, 2012; American Geriatrics Society, 2015] and the Screening Tool of Older Person’s 
Prescriptions (STOPP) – Screening Tool to Alert doctors to Right Treatment (START) criteria 
[Gallagher et al. 2008; O’Mahony et al. 2014] are probably the best known and most widely studied 
of these tools in US and European settings respectively. These tools, and others developed since the 
publication of the systematic review by Kaufmann et al. [Renom-Guiteras et al. 2015], do not 
specifically consider older people with dementia [Krӧger et al. 2015; Montastruc et al. 2013]; there is 
a paucity of studies relating to the development and application of criteria specifically for assessing 
appropriateness of medication for this patient population.  
PIP in people with dementia has been understudied to date [Montastruc et al. 2013; Johnell 2015; 
Skӧldunger et al. 2015], but is gaining research interest, as indicated by the recent publication of a 
number of studies focusing on this particularly vulnerable cohort. Much of this work, discussed 
below, has focussed on people with advanced dementia (characterised by profound cognitive 
deficits, inability to recognize family members, speech limited to fewer than 5 words, total 
functional dependence, incontinence, and inability to ambulate [Mitchell et al. 2012]) and limited 
life expectancy.  These studies are summarised in Table 1.  
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 The most significant advance in the literature in this area was the development of consensus criteria 
for appropriate prescribing by Holmes et al. [Holmes et al. 2008]. These criteria have since been 
applied in a number of other studies in the USA and Europe (Table 1). More recently, Krӧger et al. 
undertook a scoping review of criteria on medication appropriateness in severe dementia and 
characteristics of intervention studies [Krӧger et al. 2015]. This revealed that although considerable 
attention had been devoted to inappropriateness of medication use among older residents of 
nursing homes, comprehensive specific criteria were limited to the Holmes et al. list. Following the 
publication of this review, Parsons et al. presented medication appropriateness indicators for 
persons with advanced dementia specific to the UK context developed using a similar approach to 
Holmes et al.  [Parsons et al. 2015], details of which are outlined in Table 1. To the best of the 
author’s knowledge, the criteria identified by Holmes et al. (2008) and Parsons et al. (2015) 
represent the only currently available systems for identifying PIP in people with advanced dementia 
in whom a palliative approach is needed. 
Studies including people with mild-to-moderate dementia or recruiting across the full spectrum of 
disease severity are now beginning to be appear in the research literature. Summarised in Table 1, 
these studies focus on the medication regimen as a whole, or on several medications or medication 
classes. They demonstrate the high prevalence of PIP across disease severity and setting and country 
of care, and the necessity for development and validation of tools to assess appropriateness of 
prescribing specifically for people with dementia. Expanding the evidence base in this area is of 
critical importance due to the adverse health, clinical and economic outcomes associated with 
inappropriate drug use among older people with dementia [Skӧldunger et al. 2015].  
In addition to this body of work, some studies have considered misprescribing, overprescribing, or 
underprescribing of individual medications or medication classes, as outlined below. Considerable 
scope exists to improve the quality of prescribing for people with dementia in each of these areas. 
Appropriateness of prescribing of specific drug classes 
Anticholinergic medications 
Older people are commonly subjected to a high anticholinergic load or burden due to the 
widespread use of anticholinergic/antimuscarinic medications and the wide range of medications 
possessing anticholinergic side-effects (such as antihistamines, antidepressants, anti-Parkinson 
agents, antipsychotics, antispasmodics, and skeletal muscle relaxants) [Mate et al. 2015].  People 
with dementia are particularly susceptible to adverse effects associated with a high anticholinergic 
load [Sunderland et al. 1987; Sunderland et al,. 1985; Sura et al. 2013]; they have reduced levels of 
acetylcholine (a neurotransmitter critical to the neurons involved in cognition), and as a 
consequence anticholinergic medications may worsen their cognitive function [Feinberg 1993; Roe 
et al. 2002; Carnahan et al. 2004; Kemper et al. 2007; Rudolph et al. 2008; Carrière et al. 2009; Modi 
et al. 2009; Fox et al. 2011].  
Studies have demonstrated a high anticholinergic load among people with dementia; work 
conducted in the United States, Australia and the UK have reported that between 40 and 60% of 
patients with dementia use at least one anticholinergic medication [Chan et al. 2006; Bhattacharya 
et al. 2011; Sura et al. 2013; Mate et al. 2015; Cross et al. 2016), with 10 – 25% using higher potency 
anticholinergic drugs or medications with clinically significant anticholinergic activities [Bhattacharya 
et al. 2011; Sura et al. 2013; Mate et al. 2015; Palmer et al. 2015; Cross et al. 2016]. Due to the 
association of anticholinergic burden with falls, worsening cognition and worsening function [Moore 
& O’Keefe, 1999; Tune, 2001; Cao et al. 2008; Lowry et al. 2011; Uusvaara et al. 2011], clinicians 
should consider the anticholinergic properties of medications when adding to or changing patients’ 
drug regimens, with a view to minimising the anticholinergic effects [Palmer et al. 2015].  
Psychotropics  
Psychotropic drugs, including antipsychotics, anxiolytics, hypnotics, antidepressants, anticonvulsants 
and antidementia drugs, are widely prescribed for behavioural and psychological symptoms of 
dementia (BPSD) [Thompson Coon et al. 2014; van der Spek et al. 2015], which include behaviours 
such as aggression, screaming, restlessness, anxiety, hallucinations and depressive mood [Cerejeira 
et al. 2012]. These neuropsychiatric symptoms are highly prevalent in people with dementia; up to 
90% of people with Alzheimer’s disease experience at least one symptom during the course of the 
disease [Liperoti et al. 2008].  
Treatment guidelines for BPSD recommend that antipsychotics should not be used as first-line 
management; detailed assessment to rule out other treatable causes of symptoms and alternative 
nonpharmacological interventions should be tried first [Food and Drug Administration, 2005; 
National Institute for Health and Care Excellence, 2006; Food and Drug Administration, 2008; 
European Medicines Agency, 2010; Chiu et al. 2015; Foebel et al. 2016].  Antipsychotics are 
unlicensed for treatment of these symptoms [Muench & Hamer, 2010], with the exception of 
risperidone, which has approval for this indication in some countries [Langballe et al. 2014].  
Furthermore, they have demonstrated limited efficacy and have been associated with serious side-
effects, increased morbidity, exacerbation of functional and cognitive decline, and mortality 
[Schneider et al. 2005; Kales et al. 2007; Liperoti et al. 2009; Trifirò et al. 2009; Ballard et al. 2011; 
Musicco et al. 2011; Huybrechts et al. 2012; Langballe et al. 2014; Bonner et al. 2015; Foebel et al. 
2016]. Despite this, they continue to be prescribed frequently, often on an unlicensed, long-term 
basis. As a result, the appropriateness of antipsychotic use in this population is often questioned 
[Chiu et al. 2015; Foebel et al. 2016], and it has been estimated that two-thirds of prescriptions are 
unnecessary [Ballard et al. 2014]. Although rates of antipsychotic prescribing in older people with 
dementia are declining in response to warnings from agencies such as the US Food and Drug 
Administration (Food and Drug Administration 2005; Food and Drug Administration 2008), the 
European Medicines Agency [European Medicines Agency, 2010] and the UK Department of Health 
[Banerjee, 2009], antipsychotic use remains widespread, particularly in long-term care settings. 
Recent rates of antipsychotic prescribing have been reported to range from 7.4% in primary care and 
16.6% in acute care in the UK [Martinez et al. 2013; Stephens et al. 2014], to 25% across care 
settings in Germany [Schulze et al. 2013], 31% in institutional care settings in the Netherlands 
[Kleijer et al. 2014], and 40% in geriatric care settings in Sweden [Lӧvheim et al. 2006]. In the United 
States, the 2004 National Nursing Home survey (NNHS) reported that approximately one-third 
(32.9%) of nursing home residents with dementia received at least one antipsychotic medication 
[Kamble et al. 2009]. More recent figures suggest that patterns of prescribing in the US have not 
changed considerably; 23.9% of all long-stay nursing home residents received at least one 
antipsychotic medication [Centres for Medicare and Medicaid Services, 2011].  Future research 
should aim to continue to gather and apply research evidence to improve the safety and quality of 
antipsychotic prescribing, and to address a number of key unanswered questions regarding the 
mortality risk of drugs at the individual drug level, the relationship between dose and mortality, and 
the individual patient factors which may predispose or mitigate risk [Ballard et al. 2014]. 
Antibiotics 
People with dementia are susceptible to infections, including respiratory tract infections (RTIs), 
urinary tract infections (UTIs), and skin and soft tissue infections [Mitchell et al. 2009; Vandervoort 
et al. 2013]. Treatment decisions, particularly in the more advanced stages of dementia and at the 
end of life, are complex [van Der Maaden et al. 2015] and require a balance of the potential burden 
caused by treatment, the best interests of the patient, and family and patient preferences [van der 
Steen et al. 2001; Hurley & Volicer, 2002]. This complexity is due in part to the inability of patients to 
communicate their symptoms, and because typical symptoms of infections are often absent 
[Scherder et al. 2009; D’Agata et al. 2013].  
Much work has been undertaken to examine potentially inappropriate antimicrobial use in older 
people residing in long-term care settings [Zimmer et al. 1986; Warren et al. 1991; Pickering et al. 
1994; Montgomery et al. 1995; Loeb et al. 2001; Lim et al. 2012; Phillips et al. 2012; Stuart et al. 
2012; Peron et al. 2013; Sloane et al. 2014; van Buul et al. 2015], reporting asymptomatic bateriuria 
as the most common reason for potentially inappropriate antibiotic use [Pickering et al. 1994; Loeb 
et al. 2001; Nicolle, 2002; Black et al. 2006; Phillips et al. 2012; D’Agata et al. 2013; van Buul et al. 
2015]. However, there has been limited work undertaken to date to examine the appropriateness of 
antibiotic prescribing specifically in people with dementia [Mitchell et al. 2014]. One study of US 
nursing home residents with advanced dementia reported that 44% of treated episodes of 
suspected infection met minimum clinical criteria [Loeb et al. 2001] for initiation of antimicrobial 
treatment, suggesting that much of the extensive prescription of antimicrobials in advanced 
dementia may be unwarranted [Mitchell et al. 2014].  The authors reported that antibiotics were 
most likely to be initiated in the absence of minimum treatment criteria for UTIs which rely on 
subjective signs and symptoms undetectable to the observer in the absence of patient self-report. 
They highlighted the difficulty in interpreting what is “symptomatic” in people with advanced 
dementia and in applying minimum criteria for treatment.  The development of consensus criteria to 
measure appropriateness of prescribing, specific to people with dementia and comprising indicators 
of appropriate prescribing of antimicrobials, would facilitate a more judicious approach to infection 
management in this vulnerable patient population, avoiding unnecessary treatment burden and 
mitigating the threat of multidrug resistant organisms [Mitchell et al. 2014]. 
Analgesics 
It has been widely reported that approximately 50% of older people with dementia experience pain 
[Leong & Nuo, 2007; Zwakhelen et al. 2009; Barry et al. 2016], which is often chronic in nature and 
caused by musculoskeletal conditions, previous fractures or neuropathies [Hadjistavropoulus et al. 
2007; Scherder & Plooij , 2012]. Despite this, there is evidence that pain in dementia often remains 
undetected and undertreated [Hoffmann et al. 2014; Tan et al. 2015]. A number of possible reasons 
for this have been suggested; people with dementia have difficulty in expressing and communicating 
their pain [Marzinksi 1991; Ferrell et al. 1995; Cook et al. 1999; Husebo et al. 2008; Reynolds et al. 
2008], it can be difficult for observers to identify pain which can manifest in a range of behaviours 
and symptoms also indicative of other forms of distress including depression, boredom or anxiety 
[Breland et al. 2015], and physicians may be reluctant to prescribe medications, particularly opioids, 
for these patients due to higher rates of treatment complications [Closs et al. 2004; Pickering et al. 
2006; Corbett et al. 2012; Monroe et al. 2014; Breland et al. 2015; Li et al. 2015]. Furthermore, a lack 
of pharmacological studies examining the pharmacodynamic properties of analgesics in this 
vulnerable patient population [McLachlan et al. 2011] may result in treatment decisions made in the 
absence of a clear knowledge of the impact of comorbidities on the efficacy and adverse effect 
profiles of analgesics [Achterberg et al. 2013]. 
It has been hypothesised that people with dementia may perceive and express pain differently to 
cognitively intact individuals; however, to date, many studies examining pain and analgesic use in 
people with dementia have utilised pain assessment scales or instruments which are not specific to 
this patient population [Scherder et al. 2003; Corbett et al,. 2012; Tan et al. 2015]. Future research is 
required using dementia-specific pain scales [Achterberg et al. 2013; Tan et al. 2015] and considering 
the neuropathology, experience, assessment and management of pain in these vulnerable patients 
[Tan et al. 2015]. The appropriateness of pharmacological treatments for people with dementia, 
considering the use of different analgesic classes and doses, as part of a standardised approach to 
pain management, is a research priority [Tan et al. 2015]. 
Priorities for research 
Further studies of PIP in large cohorts of people with dementia and cognitive impairment, which 
include patients across the spectrum of variants and dementia severities, are required [Johnell, 
2015; Sköldunger et al. 2015]. In order to undertake these studies, it is imperative that prescribing 
appropriateness criteria specific to this patient population are developed and/or utilised, which take 
into consideration the most commonly implicated medications discussed in this narrative review; 
namely anticholinergics, psychotropics, antibiotics and analgesics, in addition to drug-drug and drug-
disease interactions.  Such criteria must consider dementia of all severities and be applicable across 
settings of care. Future work should also examine the impact of PIP on health outcomes for persons 
with dementia [Hanlon et al. 2015], an area which has received little research attention to date. 
Conclusion 
Older adults with dementia are at risk of suboptimal and potentially inappropriate prescribing. 
Evidence-based guidelines to assist physicians in prescribing for these vulnerable patients, who often 
have multiple co-morbidities and take multiple medications, are lacking. The pharmacotherapeutic 
management of these patients is an area requiring urgent research attention. 
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Table 1. Summary of studies determining medication appropriateness in people with dementia 
 
Author/Year (Country) Sample, N  Design Definition of 
Medication 
Appropriateness 
Study findings 
Holmes et al. 2008 (USA) 34 residents with 
advanced dementia 
(FAST score 6E, 7A, 7B 
or 7C [Reisberg, 1988]) 
in 3 long-term care 
facilities 
Feasibility study 
developing consensus 
recommendation for 
appropriate 
prescribing in people 
advanced dementia in 
whom palliation of 
symptoms is the 
primary goal of 
therapy, using 
modified Delphi 
consensus process (12 
geriatricians), and 
medication record 
review 
Medications 
categorised into: never, 
rarely, sometimes or 
always appropriate for 
use in patients with 
advanced dementia 
Consensus was 
reached on 
appropriateness of 
69 of 81 medications 
and medication 
classes. 5% of 221 
medications 
prescribed at 
enrolment were 
considered to be 
never appropriate, 
and 10 of 34 patients 
(29%) were taking a 
never appropriate 
medication 
Tjia et al. 2010, (USA) 323 residents  with 
advanced dementia 
(GDS score of 7 
[Reisberg et al. 1982]) 
in 22 nursing homes 
Medication record 
review of data 
collected in the 
CASCADE study 
(Mitchell et al. 2006) 
Prescribing of drugs 
deemed never 
appropriate in 
advanced dementia 
according to Holmes et 
al. (2008) 
37.5% received at 
least one medication 
considered never 
appropriate in 
advanced dementia. 
Most commonly 
implicated 
inappropriate 
medications were 
AChEIs (15.8%), lipid-
lowering agents 
(12.1%) and 
memantine (9.9%)  
Colloca et al. 2012 (Europe 
[Czech Republic, Finland, 
France, Germany, Italy, 
The Netherlands, UK] and 
Israel) 
1449 residents with 
severe cognitive 
impairment (CPS score 
of 4 – 6 [Morris et al. 
1994]) in 57 nursing 
homes 
Medication record 
review of data 
collected in the 
SHELTER study (Onder 
et al. 2012) 
Prevalence of 
prescribing drugs 
classified by Holmes et 
al. (2008) as rarely or 
never appropriate in 
advanced dementia 
Inappropriate drug 
use observed in 643 
(44.9%) of residents. 
Most commonly 
implicated 
medications were 
lipid-lowering drugs 
(9.9%), antiplatelet 
agents excluding 
acetylsalicylic acid 
(9.9%), AChEIs (7.2%) 
and antispasmodics 
(6.9%).  
Parsons et al. 2012 (UK) Residents with 
dementia (documented 
diagnosis or cognitive 
impairment indicative 
of dementia 
determined by senior 
care home staff) in 6 
residential care homes 
(n=119, timepoint 1; 
n=110, timepoint 2) 
Retrospective analysis 
of medication data 
Prescribing of 
potentially PIMs, using 
31 from 65 STOPP 
criteria. 
55 residents (46.2%) 
and 45 residents 
(40.9%) prescribed ≥ 
1 PIM at timepoints 
1 and 2 respectively. 
Long-term 
antipsychotics more 
frequently 
prescribed PIM; for 
21.0% and 19.1% of 
residents at 
timepoints 1 and 2. 
Montastruc et al. 2013 
(France) 
684 community-
dwelling people with 
mild-to-moderate AD 
(MMSE 10-26 [Folstein 
et al. 1975]) 
Analysis of medication 
data collected in 
prospective 
multicentre cohort 
study 
Prescribing of PIMs 
according to the 2003 
Beers criteria (Fick et 
al. 2003), the Laroche 
list (Laroche et al. 
2007) and a further list 
of atropinic drugs 
Approximately one-
quarter (25.3%) of 
patients were 
prescribed ≥ 1 PIM 
according to the 
Beers criteria, and 
46.8% were 
defined by the research 
team.  
prescribed at least 
one PIM according to 
the Laroche list 
46.8% of patients 
were prescribed ≥ 1 
PIM. Cerebral 
vasodilators were 
the most widely used 
class (24% of all 
prescriptions), 
followed by atropinic 
drugs (17%) and long 
half-life 
benzodiazepines 
(8.5%). Atropinic 
drugs were 
associated AChEIs in 
16% of patients. 
Toscani et al. 2013 (Italy) 245 residents in 34 
nursing homes and 165 
community dwelling 
people with advanced 
dementia (FAST score 
≥ 7) 
Medication record 
review of data 
collected in the EOLO-
PSODEC study  
Prescribing of drugs in 
appropriateness 
categories classified by 
Holmes et al. (2008)  
21.2% of all 
participants 
prescribed never or 
rarely appropriate 
medications. 
Prescribing rates did 
not differ 
significantly between 
community-dwelling 
people with 
dementia and those 
resident in nursing 
homes. 
Tjia et al. 2014 (USA) 5406 residents with 
advanced dementia 
Medication record 
review of nationwide 
Use of medications of 
questionable benefit 
2911 (53.9) of 
residents received at 
(CPS score of 6) from 
Minimum Data Set 
facilities (460 facilities)  
long-term care 
pharmacy database 
linked to the Minimum 
Data Set 
(deemed never 
appropriate in 
advanced dementia by 
Holmes et al. 2008) 
least one medication 
of questionable 
benefit. Most 
commonly 
implicated 
inappropriate 
medications were 
AChEIs (36.4%), 
memantine (25.2%) 
and lipid-lowering 
agents (22.4%) 
Hanlon et al. 2015 (USA) 1303 veterans with 
dementia (identified 
using ICD-9 codes for 
AD, VaD and other 
dementias, including 
dementia not 
otherwise specified) 
resident in 133 
Veterans Affairs 
Community Living 
Centers. Dementia 
severity defined using 
CPS and ADL 
(McConnell et al. 2002) 
scores. 
Analysis of medication 
data collected during 
retrospective 
descriptive study 
For patients with mild-
moderate dementia, 
underuse was 
operationally defined 
as no pharmacy 
dispensing of an AChEI. 
In the severe dementia 
group, overuse was 
defined as use of 
medications/classes for 
which patients were 
unlikely to derive 
benefit given their 
limited life expectancy 
and the risk of adverse 
drug reactions 
(medications defined 
by Holmes et al.  [2008] 
as “never appropriate” 
for use in these 
patients). PIM use was 
defined in both groups 
Rates of PIP were 
27.2% for people 
with mild-to-
moderate dementia 
and 25.1% for those 
with severe 
dementia 
respectively. 
Potential underuse 
was observed in 
70.2% of people with 
mild-to-moderate 
dementia, and 
potential overuse in 
36.1% of those with 
severe dementia 
(23.4% receiving 
AChEIs and 12.8% a 
lipid-lowering agent). 
Approximately one-
quarter (25.1%) of 
people with severe 
as evidence of clinically 
important drug-disease 
interactions 
(medications which 
may worsen cognitive 
function: 
anticholinergics, 
barbiturates, and 
benzodiazepine 
receptor agonists) or 
drug-drug interactions 
(highly anticholinergic 
drugs that can block 
the pharmacodynamics 
effects of AChEIs, or 
drugs which can inhibit 
the metabolism of 
galantamine or 
donepezil) 
dementia had 
evidence of 
inappropriate 
prescribing as a 
result of a drug-drug 
or drug-disease 
interaction. In 
people with severe 
dementia, 
antipsychotic use 
was associated with 
all three types of 
suboptimal 
prescribing. 
Parsons et al. 2015 (UK) 15 residents with 
advanced dementia 
(FAST score between 
6E and 7F) from 3 
nursing homes 
Feasibility study 
developing consensus 
recommendation for 
appropriate 
prescribing in people 
advanced dementia in 
whom palliation of 
symptoms is the 
primary goal of 
therapy, using Delphi 
consensus process (9 
clinicians including 4 
geriatricians, 4 old age 
psychiatrists and 1 
Medications 
categorised into: never, 
rarely, sometimes or 
always appropriate 
14 residents at 
baseline were taking 
≥ 1 never 
appropriate 
medication, and 
25.7% of 
medications 
prescribed were 
never appropriate. 
Use of never 
appropriate 
medications did not 
change significantly 
at 3, 6 or 9 month 
neurologist), and 
longitudinal 
prospective medication 
record review  
timepoints. For 
residents who died 
during data 
collection (n=4), 
there was a decrease 
in prescribing of 
never appropriate 
medications (12.0) 
and an increase in 
prescribing of always 
appropriate 
medications (28.0%) 
Sköldunger et al. 2015 
(Sweden) 
4108 older people in 
the SNAC study 
(Lagergren et al. 2004), 
including 319 with 
dementia (diagnosed 
by a physician, 
according to DSM-III-R 
[American Psychiatric 
Association, 1987] 
Analysis of medication 
data collected during 
prospective 
longitudinal cohort 
SNAC study 
Prescribing of 
inappropriate drugs 
defined as exposure to 
at least one of the 
following: concurrent 
use of three of more 
psychotropic drugs, 
drugs with 
anticholinergic 
properties, long-acting 
benzodiazepines, and 
serious drug-drug 
interactions as defined 
by national guidelines. 
Prevalence of 
inappropriate drug 
use was significantly 
higher in the cohort 
with dementia 
(27.3%) than for 
participants without 
dementia (n=3783), 
in whom prevalence 
was reported at 
11.8%. For people 
with dementia, 
inappropriate drug 
use was associated 
with an increased 
risk of hospitalisation 
but the association 
between 
inappropriate drug 
use and mortality 
was not significant. 
Cross et al. 2016 
(Australia) 
964 community-
dwelling patients with 
mild cognitive 
impairment (Petersen 
criteria [Winblad et al. 
2004) or dementia 
(DSM-IV), attending 9 
memory clinics 
Analysis of medication 
data from the PRIME 
multicentre 
observational study 
(Brodaty et al. 2011) 
Prescribing of PIMs 
relating to cognitive 
impairment, utilising 
Beers 2012 criteria 
(Campanelli, 2012) and 
the STOPP 2014 criteria 
(O’Mahony et al. 
2014). 
21.4% of patients 
were using ≥ 1 
PIMcog, and 4.8% 
were using ≥ 2; 
medications most 
commonly 
implicated were 
sedatives and 
anticholinergics. 
 
